Adding Quercetin or Alpha Lipoic Acid to Metformin to Improve Symptoms and Blood Markers in Women with Polycystic Ovary Syndrome

What this Trial Is About

Researchers are evaluating whether adding Quercetin or Alpha-Lipoic Acid ALA to standard metformin therapy can improve hormone levels, metabolic health, symptoms, and quality of life in women with polycystic ovary syndrome PCOS. The study focuses on differences in hormonal balance, blood sugar control, cholesterol, antioxidant markers, medication adherence, and patient-reported well-being. This Phase 2 trial is sponsored by Al-Mustansiriyah University and targets women newly diagnosed with PCOS who meet specific clinical criteria. Participants will be randomly assigned to one of three groups for a 3-month treatment period metformin 500 mg daily alone, metformin 500 mg plus Quercetin 500 mg daily, or metformin 500 mg plus ALA 600 mg sustained release daily. All treatments are taken orally once daily after a meal. Researchers will monitor the effects of these regimens on hormonal and metabolic markers, along with quality of life and medication adherence. During the study, participants will provide fasting blood samples at the start and after 3 months to measure hormones, glucose, insulin, lipids, and oxidative stress biomarkers. They will complete questionnaires assessing quality of life and medication adherence, undergo physical measurements including weight, BMI, waisthip circumference, and blood pressure, and report any side effects. Safety and overall benefits will be evaluated throughout the study.

Effects of Adding Quercetin or Alpha Lipoic Acid to Usual Care on Symptoms and Blood Markers in Iraqi Women With Polycystic Ovary Syndrome